864498-49-7

Basic information

• Product Name: Methyl 3-cyclopropyl-2-Methyl-3-oxopropanoate
• Synonyms: Methyl 3-cyclopropyl-2-Methyl-3-oxopropanoate
• CAS NO: 864498-49-7
• Molecular Formula: C₈H₁₂O₃
• Molecular Weight: 156.17908
• Mol File: 864498-49-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 205.7±13.0 °C(Predicted)
• Appearance: /
• Density: 1.132±0.06 g/cm3(Predicted)
• PKA: 11.88±0.20(Predicted)
• CAS DataBase Reference: Methyl 3-cyclopropyl-2-Methyl-3-oxopropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-cyclopropyl-2-Methyl-3-oxopropanoate(864498-49-7)
• EPA Substance Registry System: Methyl 3-cyclopropyl-2-Methyl-3-oxopropanoate(864498-49-7)

Safety Data

• Hazardous Substances Data: 864498-49-7(Hazardous Substances Data)

Usage

General Description

Methyl 3-cyclopropyl-2-methyl-3-oxopropanoate is a chemical compound with the molecular formula C8H12O3. It is a colorless liquid with a fruity odor and is commonly used as a flavoring agent and intermediate in the synthesis of pharmaceuticals and other organic compounds. Methyl 3-cyclopropyl-2-Methyl-3-oxopropanoate is classified as an ester, as it is formed from the reaction between a carboxylic acid and an alcohol. It is also known by the chemical name "methyl 3-cyclopropyl-2-methyl-3-oxopropanoate" and has a molecular weight of 156.18 grams per mole. Overall, methyl 3-cyclopropyl-2-methyl-3-oxopropanoate has diverse applications and is an important building block in organic chemistry.

Upstream product

• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 74-88-4 methyl iodide 

Relevant articles and documents

Enantioselective synthesis of α-methyl-β-cyclopropyldihydrocinnamates

α- and β-substitution of dihydrocinnamates has been shown to increase the biological activity of various drug candidates. Recently, we identified enantio- and diastereopure α-methyl-β-cyclopropyldihydrocinnamates to be important pharmacophores in one of our drug discovery programs and endeavored to devise an asymmetric hydrogenation strategy to improve access to this valuable framework. We used high throughput experimentation to define stereoconvergent Suzuki-Miyaura cross-coupling conditions affording (Z)-α-methyl-β-cyclopropylcinnamates and subsequent ruthenium-catalyzed asymmetric hydrogenation conditions affording the desired products in excellent enantio- and diastereoselectivities. These conditions were executed on multigram to kilogram scale to provide three key enantiopure α-methyl-β-cyclopropyldihydrocinnamates with high selectivity.

Design and Synthesis of Novel, Selective GPR40 AgoPAMs

GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secretion

[7,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.